Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Korea University Anam Hospital, Korea University Medical College, Seoul, Republic of Korea.
Department of Internal Medicine, Korea University Anam Hospital, Korea University Medical College, Seoul, Republic of Korea.
Int J Surg. 2022 Aug;104:106753. doi: 10.1016/j.ijsu.2022.106753. Epub 2022 Jul 5.
External beam radiation therapy (EBRT) and surgery are local treatment modalities for patients with hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). This meta-analysis aims to evaluate the effectiveness and feasibility of these treatment modalities.
PubMed, Medline, Embase, and Cochrane Library databases were systematically searched until April 2021. The primary endpoint was overall survival (OS) of the patients; the adverse effects of the treatment were also investigated.
A total of 59 studies involving 9525 patients with HCC and PVT were included in this meta-analysis. All studies were non-randomized series, including seven comparative studies, and the remainder were single-arm studies or studies with comparative groups other than surgery or EBRT. The pooled rates of Child-Pugh class A were 74.6% and 95.3% in the EBRT and surgery arms, respectively, and the pooled main PVT rates were 40.7% and 15.5% in the EBRT and surgery arms, respectively (p < 0.001). Pooled 1- and 2-year OS rates of the EBRT arm were 44.1% (95% CI:40.3-48.0) and 21.7% (95% CI:18.9-24.8), respectively. In the subgroup of EBRT studies without main PVT, pooled 1- and 2-year OS rates were 59.9% (95% CI:48.9-70.1) and 30.5% (95% CI:15.2-51.8), respectively. In the surgery arm, the correlation rates were 62.8% (95% CI:55.0-70.0) and 42.5% (95% CI:34.4-51.0), respectively. The pooled 1-, and 2-year OS rates of surgery arm were significantly higher than those of EBRT arm (ps < 0.001), and not significantly different with the EBRT subgroup without main PVT (p = 0.762, 0.353, respectively). In studies of surgery accompanied by EBRT, the 1- and 2-year OS rates were 77.1% (95% CI:69.6-83.2) and 45.4% (95% CI:19.8-73.7), respectively. The pooled rates of grade≥3 toxicities ranged from 1.8 to 4.3%, depending on the type.
Surgery can yield a favorable survival outcome, whereas EBRT can be widely considered for patients, including those with inferior clinical profiles. Further studies are warranted to determine the possibility of improving the clinical outcomes of surgery accompanied by EBRT.
外照射放疗(EBRT)和手术是伴有门静脉血栓形成(PVT)的肝细胞癌(HCC)患者的局部治疗方式。本荟萃分析旨在评估这些治疗方法的有效性和可行性。
系统检索了 PubMed、Medline、Embase 和 Cochrane 图书馆数据库,截至 2021 年 4 月。主要终点是患者的总生存率(OS);还调查了治疗的不良反应。
共纳入 59 项研究,涉及 9525 例伴有 PVT 的 HCC 患者。所有研究均为非随机系列研究,包括 7 项对照研究,其余为单臂研究或除手术或 EBRT 以外的对照研究。EBRT 组和手术组的 Child-Pugh 分级 A 的汇总率分别为 74.6%和 95.3%,EBRT 组和手术组的主要 PVT 汇总率分别为 40.7%和 15.5%(p<0.001)。EBRT 组的 1 年和 2 年 OS 率分别为 44.1%(95%CI:40.3-48.0)和 21.7%(95%CI:18.9-24.8)。在没有主要 PVT 的 EBRT 研究亚组中,1 年和 2 年 OS 率分别为 59.9%(95%CI:48.9-70.1)和 30.5%(95%CI:15.2-51.8)。手术组的相关率分别为 62.8%(95%CI:55.0-70.0)和 42.5%(95%CI:34.4-51.0)。手术组的 1 年和 2 年 OS 率明显高于 EBRT 组(p<0.001),与无主要 PVT 的 EBRT 亚组无显著差异(p=0.762,0.353)。在手术联合 EBRT 的研究中,1 年和 2 年 OS 率分别为 77.1%(95%CI:69.6-83.2)和 45.4%(95%CI:19.8-73.7)。根据类型,≥3 级毒性的汇总率为 1.8%至 4.3%。
手术可以获得良好的生存结果,而 EBRT 可以广泛应用于包括临床状况较差的患者。需要进一步研究以确定改善手术联合 EBRT 临床结果的可能性。